Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Show more

Location: 11 Commerce Drive, Cranford, NJ, 07016, United States | Website: https://citiuspharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

20.75M

52 Wk Range

$0.65 - $15.25

Previous Close

$1.22

Open

$1.24

Volume

555,340

Day Range

$1.10 - $1.24

Enterprise Value

16.55M

Cash

6.089M

Avg Qtr Burn

-5.146M

Insider Ownership

2.90%

Institutional Own.

5.46%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.